122 related articles for article (PubMed ID: 37452621)
1. Effects of single nucleotide polymorphisms of the folylpolyglutamate synthase gene on pemetrexed administration-induced nephropathy.
Mitarai Y; Tanino R; Nakashima K; Hotta T; Isobe T; Tsubata Y
Br J Clin Pharmacol; 2023 Dec; 89(12):3551-3560. PubMed ID: 37452621
[TBL] [Abstract][Full Text] [Related]
2. A folylpoly-γ-glutamate synthase single nucleotide polymorphism associated with response to pemetrexed treatment combined with platinum for non-small cell lung cancer.
Fukuda S; Oguri T; Kunii E; Sone K; Uemura T; Takakuwa O; Maeno K; Kanemitsu Y; Ohkubo H; Takemura M; Ito Y; Niimi A
Lung Cancer; 2016 Dec; 102():15-20. PubMed ID: 27987582
[TBL] [Abstract][Full Text] [Related]
3. Effect of renal function on pemetrexed-induced haematotoxicity.
Ando Y; Hayashi T; Ujita M; Murai S; Ohta H; Ito K; Yamaguchi T; Funatsu M; Ikeda Y; Imaizumi K; Kawada K; Yasuda K; Yamada S
Cancer Chemother Pharmacol; 2016 Jul; 78(1):183-9. PubMed ID: 27286996
[TBL] [Abstract][Full Text] [Related]
4. Nitric oxide (NO) enhances pemetrexed cytotoxicity via NO‑cGMP signaling in lung adenocarcinoma cells in vitro and in vivo.
Nagai H; Yasuda H; Hatachi Y; Xue D; Sasaki T; Yamaya M; Sakamori Y; Togashi Y; Masago K; Ito I; Kim YH; Mio T; Mishima M
Int J Oncol; 2012 Jul; 41(1):24-30. PubMed ID: 22552400
[TBL] [Abstract][Full Text] [Related]
5. Pemetrexed induced acute kidney injury in patients with non-small cell lung cancer: reversible and chronic renal damage.
Rombolà G; Vaira F; Trezzi M; Chiappini N; Falqui V; Londrino F
J Nephrol; 2015 Apr; 28(2):187-91. PubMed ID: 24986522
[TBL] [Abstract][Full Text] [Related]
6. Biomarker analysis in a phase III study of pemetrexed-carboplatin versus etoposide-carboplatin in chemonaive patients with extensive-stage small-cell lung cancer.
Smit EF; Socinski MA; Mullaney BP; Myrand SP; Scagliotti GV; Lorigan P; Reck M; Ciuleanu T; von Pawel J; Karaseva NA; Szczesna A; Ohannesian D; Powell E; Hozak RR; Hong S; Guba SC; Thatcher N
Ann Oncol; 2012 Jul; 23(7):1723-9. PubMed ID: 22186609
[TBL] [Abstract][Full Text] [Related]
7. Comparative Effectiveness of Pemetrexed-platinum Doublet Chemotherapy With or Without Bevacizumab as First-line Therapy for Treatment-naive Patients With Advanced Nonsquamous Non-small-cell Lung Cancer in China.
Li X; Abbas M; Li Y; Teng Y; Fang Y; Yu S; Wen Y; Wang L; Shi M
Clin Ther; 2019 Mar; 41(3):518-529. PubMed ID: 30846285
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and toxicity of maintenance therapy with bevacizumab plus pemetrexed versus bevacizumab/pemetrexed alone for stage IIIB/IV nonsquamous non-small cell lung cancer: A meta-analysis of randomized controlled trials.
Liu M; Luo N; Fang Z; Liu Q; Yi F; Wei Y; Zhang X; Zhang W
J Clin Pharm Ther; 2022 Feb; 47(2):157-167. PubMed ID: 34617297
[TBL] [Abstract][Full Text] [Related]
9. Combined effect of ERCC1 and ERCC2 polymorphisms on overall survival in non-squamous non-small-cell lung cancer patients treated with first-line pemetrexed/platinum.
Liao WY; Ho CC; Tsai TH; Chen KY; Shih JY; Yu CJ
Lung Cancer; 2018 Apr; 118():90-96. PubMed ID: 29572009
[TBL] [Abstract][Full Text] [Related]
10. [Association between Efficacy of Pemetrexed and EGFR Mutation Status for EGFR Mutated Lung Carcinoma].
Kogure Y; Saka H; Imaizumi K
Gan To Kagaku Ryoho; 2016 Jun; 43(6):733-5. PubMed ID: 27306810
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426.
Adjei AA; Mandrekar SJ; Dy GK; Molina JR; Adjei AA; Gandara DR; Ziegler KL; Stella PJ; Rowland KM; Schild SE; Zinner RG
J Clin Oncol; 2010 Feb; 28(4):614-9. PubMed ID: 19841321
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of changes in renal function in PARAMOUNT: a phase III study of maintenance pemetrexed plus best supportive care versus placebo plus best supportive care after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer.
Middleton G; Gridelli C; De Marinis F; Pujol JL; Reck M; Ramlau R; Parente B; Pieters T; Visseren-Grul CM; San Antonio B; John WJ; Zimmermann AH; Chouaki N; Paz-Ares L
Curr Med Res Opin; 2018 May; 34(5):865-871. PubMed ID: 29424248
[TBL] [Abstract][Full Text] [Related]
13. Correlation between polymorphisms of the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer: a North Central Cancer Treatment Group-based exploratory study.
Adjei AA; Salavaggione OE; Mandrekar SJ; Dy GK; Ziegler KL; Endo C; Molina JR; Schild SE; Adjei AA
J Thorac Oncol; 2010 Sep; 5(9):1346-53. PubMed ID: 20651609
[TBL] [Abstract][Full Text] [Related]
14. Treatment with or without bevacizumab as a first-line and maintenance therapy for advanced non-squamous non-small cell lung cancer: A retrospective study.
Jun N; Hanping W; Xiaoyan S; Yan X; Mengzhao W; Xiaotong Z; Li Z
Thorac Cancer; 2020 Jul; 11(7):1869-1875. PubMed ID: 32406994
[TBL] [Abstract][Full Text] [Related]
15. Mutation Screening and Association Study of the Folylpolyglutamate Synthetase (FPGS) Gene with Susceptibility to Childhood Acute Lymphoblastic Leukemia.
Piwkham D; Siriboonpiputtana T; Beuten J; Pakakasama S; Gelfond JA; Paisooksantivatana K; Tomlinson GE; Rerkamnuaychoke B
Asian Pac J Cancer Prev; 2015; 16(11):4727-32. PubMed ID: 26107232
[TBL] [Abstract][Full Text] [Related]
16. Polymorphisms in TS, MTHFR and ERCC1 genes as predictive markers in first-line platinum and pemetrexed therapy in NSCLC patients.
Krawczyk P; Kucharczyk T; Kowalski DM; Powrózek T; Ramlau R; Kalinka-Warzocha E; Winiarczyk K; Knetki-Wróblewska M; Wojas-Krawczyk K; Kałakucka K; Dyszkiewicz W; Krzakowski M; Milanowski J
J Cancer Res Clin Oncol; 2014 Dec; 140(12):2047-57. PubMed ID: 25028118
[TBL] [Abstract][Full Text] [Related]
17. A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous non-small cell lung cancer.
Wehler T; Thomas M; Schumann C; Bosch-Barrera J; Viñolas Segarra N; Dickgreber NJ; Dalhoff K; Sebastian M; Corral Jaime J; Alonso M; Hynes SM; Lin J; Hurt K; Bence Lin A; Calvo E; Paz-Ares L
Lung Cancer; 2017 Jun; 108():212-216. PubMed ID: 28625637
[TBL] [Abstract][Full Text] [Related]
18. Randomized phase II study of pemetrexed or pemetrexed plus bevacizumab for elderly patients with previously untreated non-squamous non-small cell lung cancer: Results of the Lung Oncology Group in Kyushu (LOGIK1201).
Fukuda M; Kitazaki T; Ogawara D; Ichiki M; Mukae H; Maruyama R; Nakagaki N; Shimada M; Ikeda T; Kishimoto J; Harada T; Seto T; Ebi N; Takayama K; Okamoto I; Ichinose Y; Sugio K
Lung Cancer; 2019 Jun; 132():1-8. PubMed ID: 31097081
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of carboplatin and pemetrexed as first-line chemotherapy for non-squamous non-small cell lung cancer, and correlation between the efficacy/toxicity and genetic polymorphisms associated with pemetrexed metabolism: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0902.
Kanazawa K; Yokouchi H; Wang X; Ishida T; Fujita Y; Fujiuchi S; Harada T; Harada M; Takamura K; Oizumi S; Kinoshita I; Katsuura Y; Honjo O; Kojima T; Dosaka-Akita H; Isobe H; Munakata M; Nishimura M;
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1149-57. PubMed ID: 25294632
[TBL] [Abstract][Full Text] [Related]
20. Final results from a Phase II study of pemetrexed and cisplatin with concurrent thoracic radiation after Pem-Cis induction in patients with unresectable locally advanced non-squamous non-small cell lung cancer (NSCLC).
Garrido P; Engel-Riedel W; Serke M; Giraud P; Ricardi U; Vallejo C; Visseren-Grul C; Ameryckx S; Soldatenkova V; Chouaki N; Novello S
Lung Cancer; 2015 May; 88(2):160-6. PubMed ID: 25758556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
